Abstract 1903 Assessing the Retention of a Hydroxyapatite-Binding Peptide in Live Tissues

One in eight women are diagnosed with breast cancer, and between 20 and 30% of these diagnoses will become metastatic1,2. Bone metastases are the most common type of metastasis in breast cancer, and these occur when the cancerous cells from the breast tissue enter the blood circulation and migrate to bones. The current standard of care for bone metastasis is chemotherapy, hormonal therapy, and immunotherapy, with increasing interest in targeted therapies3. The pitfall of these treatments is that they are systemic, damaging healthy cells and cancer cells alike.